NICEATM, National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods, RTP, NC, USA.
National Centre for the Replacement, Refinement and Reduction of Animals in Research, London, UK.
Drug Discov Today. 2021 Nov;26(11):2496-2501. doi: 10.1016/j.drudis.2021.06.020. Epub 2021 Jul 28.
The pharmaceutical industry is constantly striving for innovative ways to bridge the translational gap between preclinical and clinical drug development to reduce attrition. Substantial effort has focused on the preclinical application of human-based microphysiological systems (MPS) to better identify compounds not likely to be safe or efficacious in the clinic. The Coronavirus 2019 (COVID-19) pandemic provides a clear opportunity for assessing the utility of MPS models of the lungs and other organ systems affected by the disease in understanding the pathophysiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and in the development of effective therapeutics. Here, we review progress and describe the establishment of a global working group to coordinate activities around MPS and COVID-19 and to maximize their scientific, human health, and animal welfare impacts.
制药行业一直在努力寻找创新方法，以缩小临床前和临床药物开发之间的转化差距，从而减少药物淘汰。大量的工作集中在临床前应用基于人体的微生理系统 (MPS) 上，以更好地识别那些在临床上不太可能安全有效的化合物。2019 年冠状病毒病 (COVID-19) 大流行提供了一个明确的机会，可以评估肺部和其他受疾病影响的器官系统的 MPS 模型在了解严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 的病理生理学和开发有效治疗方法方面的效用。在这里，我们回顾了进展情况，并描述了建立一个全球工作组来协调围绕 MPS 和 COVID-19 的活动，以最大限度地发挥它们在科学、人类健康和动物福利方面的影响。
